Deal facts
- Buyer
- VoxelDox Therapeutics, Inc.
- Target
- Imunon, Inc.
- Deal value
- Not disclosed
- Announced
- 21 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares, earn-out
Sources
VoxelDox Therapeutics, Inc. has agreed to acquire assets from Imunon, Inc. in a transaction announced on 21 October 2026. Both companies are based in the United States and operate within the healthcare sector. The specific financial value of this asset sale has not been disclosed. Instead, the consideration for the deal consists of shares and an earn-out component. This structure suggests a performance-based element to the payment, alongside equity issuance. The transaction is currently at the firm intention stage, with no completion date reported. As the deal is not yet finalized, the transfer of assets remains pending. The healthcare industry often involves complex asset transfers, particularly when intellectual property or specific product lines are involved. However, no further details regarding the specific assets being transferred are provided in the available data. The parties have indicated a firm intention to proceed, but the final closing of the transaction has not occurred. Regulatory or internal approvals may still be required before the deal can be completed. The lack of a disclosed price makes it difficult to assess the scale of the acquisition relative to the companies' market capitalisations. Nevertheless, the agreement marks a significant step in the relationship between these two US-based healthcare entities. The transaction is subject to customary closing conditions.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
VoxelDox Therapeutics, Inc. firm intention to acquire Imunon, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On October 20, 2026, Imunon, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with VoxelDox Therapeutics, Inc. (“ VoxelDox ”), pursuant to which the Company agreed to sell to VoxelDox the Company’s assets relating to ThermoDox®, a heat-activated liposomal formulation of doxorubicin (the “ Purchased As
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.
BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…
- Buyer
- BioNTech US Inc.
- Target
- Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
- Deal value
- USD 205,000,000
- Deal type
- asset sale
Abeona Therapeutics Inc. acquires APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics Inc. bought substantially all assets related to the research, development, manufacture and commercialization of APT-1011 from Ellodi Pharmaceuticals,…
- Buyer
- Abeona Therapeutics Inc.
- Target
- APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
- Deal value
- USD 20,000,000
- Deal type
- asset sale
CorMedix Inc. to acquire substantially all assets of Heron Therapeutics, Inc.
CorMedix Inc. (Nasdaq: CRMD) and Heron Therapeutics, Inc. (Nasdaq: HRTX) announced on 9 November 2026 that they had entered into a definitive asset purchase agreement, s…
- Buyer
- CorMedix Inc.
- Target
- Substantially all assets of Heron Therapeutics, Inc.
- Deal value
- USD 222,600,000
- Deal type
- asset sale
Rockwell Medical, Inc. to acquire Vantive's in-center hemodialysis business
Rockwell Medical, Inc. signed an Equity and Asset Purchase Agreement on November 2, 2026 with Vantive Limited, a Jersey company, to acquire Vantive's in-center hemodialy…
- Buyer
- Rockwell Medical, Inc.
- Target
- Vantive in-center hemodialysis business
- Deal value
- USD 125,000,000
- Deal type
- asset sale
Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets
Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase…
- Buyer
- Biossil Labs Inc.
- Target
- Theriva Biologics ribaxamase and SYN-006 assets
- Deal value
- USD 350,000
- Deal type
- asset sale
Buyer history
VoxelDox Therapeutics, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive